CAGR of 6.9% forecast for global psoriatic arthritis market

The psoriatic arthritis (PsA) market was valued at $4.7 billion in 2018 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan), and it is expected to grow to $9.2 billion by 2028 at a compound annual growth rate (CAGR) of 6.9%, according to analytics company GlobalData.

According to the company’s latest report,  ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’, growth will mainly be driven by the launch  of five new pipeline agents (which include injectable anti-interleukins and oral Janus Kinase [JAK] inhibitors) as well as increasing prevalence, diagnostic, and treatment rates.

Sun Pharmaceutical’s (BSE: 524715) Ilumya/Ilumetri (tildrakizumab) and UCB’s (Euronext Brussels: UCB) bimekizumab join a large roster of injectable anti-interleukins, which includes such members Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab), Novartis’ (NOVN: VX) Cosentyx (secukinumab), and Eli Lilly’s (NYSE: LLY) Taltz (ixekizumab). This growing class is set to challenge the branded TNF-inhibitors, the current standard of care. Combined with existing therapies, anti-interleukins are expected to earn $4.1 billionn in 2028 and capture 60.9% of global PsA sales.

Oral JAK inhibitors also represent a rapidly growing drug treatment class; AbbVie’s (NYSE: ABBV) Rinvoq (upadacitinib), Gilead Sciences (Nasdaq: GILD)/Galapagos’ (Euronext: GLPG) filgotinib, and Pfizer’s (NYSE: PFE) brepocitinib tosylate will join Pfizer’s Xeljanz (tofacitinib), the only JAK inhibitor currently available for PsA. The JAK inhibitor class is expected to grow to $261.0 million by 2028.